• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Autism and Developmental Disorders >Brief Report: Acamprosate in Fragile X Syndrome
【24h】

Brief Report: Acamprosate in Fragile X Syndrome

机译：简要报告：阿坎酸易碎X综合征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.
机译：谷氨酸能功能障碍与脆性X综合征（FXS）的病理生理有关。我们报道了阿坎酸的首次试验，该药物对mGluR5具有拮抗作用，在三名患有FXS和自闭症的成年人中进行了试验。回顾了描述3例FXS患者使用阿坎酸进行开放标签治疗并合并自闭症的医学记录。在所有三名患者中，阿坎酸与语言交流改善有关。三名患者在平均21.3周的治疗中接受了阿坎酸。所有患者均显示临床总体获益，如临床总体印象改善量表所评估。明显的沟通改善是出乎意料的，并且可能对FXS的治疗以及特发性自闭症产生潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号